Quviviq is a novel dual orexin receptor antagonist that was approved by the US FDA in 2022 for the treatment of insomnia in adults. This article will systematically introduce the core information of Quviviq, including its pharmacological effects, standardized usage and precautions, so as to provide reference for the rational use of drugs in clinical practice.

Instructions for Quviviq

Quviviq represents a new direction in the treatment of insomnia drugs, and the content of its instructions reflects the scientific and rigorous nature of innovative drugs. A complete understanding of the label is of key guiding significance for the effective use of this drug.

Basic Information

It is developed and produced by the Swiss company Alschwil, and the trade name is QUVIVIQ. The main ingredient is Daridorexant, which is available in 25mg and 50mg film-coated tablets with an expiration date of 24 months.

Approval status

It was approved for marketing by the US FDA in January 2022 and has not yet been approved in Chinese mainland. It needs to be obtained through formal cross-border channels, and special attention needs to be paid to the authenticity of drugs when purchasing.

Core features

As an orexin receptor antagonist, it works by selectively blocking arousal signals and does not directly inhibit the central nervous system, reducing the risk of dependence on traditional sleeping pills.

Quviviq's innovative role has laid the foundation for its clinical application.

Quviviq(Daridorexant) action and efficacy, usage and dosage

The therapeutic value of Quviviq is reflected in its unique pharmacological effects and standardized drug regimens. Rational use can lead to the best treatment results for patients with insomnia.

pharmachologic effect

Selectively antagonizes OX1R and OX2R receptors and regulates the sleep-wake cycle. Sleep is improved by inhibiting wakefulness signals rather than overall, and the after-effects are less severe the next day.

Indications

It is specifically used to treat insomnia in adults, especially the two types of difficulty falling asleep and sleep maintenance disorders. Not suitable for children and patients with severe hepatic impairment.

Medication specifications

The recommended dose is 25-50mg/day, taken 30 minutes before bedtime. Patients with moderate hepatic impairment should reduce the dose to 25mg and avoid concomitant use with strong CYP3A4 inhibitors. Onset of action may be delayed when taken after a meal.

The standardized use of Quviviq is an important condition for efficacy, but it is equally important to have a thorough understanding of its potential risks. Next, we will focus on the issues that need to be vigilant during the use of drugs.

Quviviq side effects, precautions

Medication management of Quviviq is a critical part of treatment success. Fully understanding its adverse reactions and special precautions is helpful for risk prevention and control and timely intervention.

Common reactions

Headache (≥5%), daytime sleepiness, and fatigue are most common. Older patients should be especially aware of the risk of falls, and avoid driving and precise manipulation during the medication.

Special Risks

May cause neurological symptoms such as sleep paralysis and hallucinations. Rarely, complex sleep behaviors (eg, sleep driving) occur and should be discontinued as soon as they occur.

Important Warning

It is forbidden to take it with alcohol, and it should be used with caution in combination with other central nervous system inhibitors. Patients with depression require enhanced monitoring of suicide risk. Patients with respiratory dysfunction should use it under the guidance of a physician.

The use of Quviviq requires the attention of both doctors and patients. From pharmacological effects to clinical practice, this innovative drug provides a new option for the treatment of insomnia, and only rational application can exert maximum value.